INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Trial ID or NCT#

NCT03491683

Status

not recruiting iconNOT RECRUITING

Purpose

Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).

Official Title

An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)

Eligibility Criteria

Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Seema Nagpal, MD
Seema Nagpal, MD
Neuro-oncologist
Clinical Professor, Adult Neurology Clinical Professor (By courtesy), Neurosurgery
Reena Thomas, MD PhD
Reena Thomas, MD PhD
Neuro-oncologist
Clinical Professor, Adult Neurology Clinical Professor (By courtesy), Neurosurgery
Chirag Patel, MD, PhD

Contact us to find out if this trial is right for you.

Contact

Stephanie Lewis
650-723-0381

View on ClinicalTrials.gov